Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency

Journal of Endocrinological Investigation

Volumn 26, Issue 10, 2003, Pages 1001-1007

  Ozbey N ^a   Telci, A ^a   Cakatay, U ^a   Yurci, A ^a   Molvalilar, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Hypopituitarism; Oxidative protein damage; Oxidative stress; Oxidized LDL; Premature atherosclerosis

Indexed keywords

3 NITROTYROSINE; CARBONYL DERIVATIVE; DESMOPRESSIN; GLUCOCORTICOID; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN; SEX HORMONE; THIOL; THYROXINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE DURATION; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPITUITARISM; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RISK FACTOR; SUBSTITUTION THERAPY; VASCULARIZATION;

EID: 0345737280     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03348199     Document Type: Article

References (43)

1. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 366: 285-8.
2. Bates AS, Hoff WV, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81: 1169-72.
3. Bülow B, Hagmar L, Mikoczy Z, Nordström C-J, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997, 46: 75-81.
4. Tomlinson JW, Holden N, Hills RK, et al. and the West Midlands Prospective Hypopituitary Study Group 2001. Association between premature mortality and hypopituitarism. Lancet 2001, 357: 425-31.
5. Stavrou S, Kleinberg DL. Diagnosis and management of GH deficiency in adults. Endocrinol Metab Clin North Am 2001, 30: 545-63.
6. Markussis V, Besyah SA, Fischer C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high resolution ultrasonography in symptom free hypopituitary adults. Lancet 1992, 340: 1188-92.
7. Capaldo B, Patti L, Pliviero U, et al. Increased arterial intima media thickness in childhood onset growth hormone deficiency. J Clin Endocrinol Metab 1997, 82: 1373-81.
8. Markussis V, Beshyah SA, Fischer C, Parker K, Nicolaides AN, Johnston DG. Abnormal carotid artery wall dynamics in symptom free hypopituitary adults. Eur J Endocrinol 1997, 136: 157-64.
9. Evans LM, Davis JS, Anderson RA, et al. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000, 142: 254-62.
10. Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2001, 86: 5774-81.
11. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J Clin Endocrinol Metab 1998, 83: 382-95.
12. Besyah SA, Johnston DG. Cardiovascular disease risk and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 1999, 50: 1-15.
13. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993, 129: 125-200.
14. Stadtman ER, Levine RL. Protein oxidation. Ann NY Acad Sci 2000, 899: 191-8.
15. Hazell LJ, Baernthale G, Stocker R. Correlation between intima-to-media ratio, apoprotein B-100, myeloperoxidase and hypochlorite-oxidized proteins in human atherosclerosis. Free Radic Biol Med 2000, 31: 1254-62.
16. Dean RT, Fus S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997, 324: 1-18.
17. Signorelli SS, Neri S, Di Pino L, et al. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. Clin Exp Med 2001, 1: 9-12.
18. Reznick AZ, Packer L. Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol 1994, 233: 357-63.
19. Shanlin FU, Davies MJ, Stocker R, Dean RT. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem J 1998, 333: 519-25.
20. Dominguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 21: 1736-42, 1998.
21. Telci A, Çakatay U, Kayah R, et al. Oxidative protein damage in plasma of type 2 diabetic patients. Horm Metab Res 2000, 32: 40-3.
22. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994, 233: 381-5.
23. Bourdon E, Loreau D, Blache D. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 1999, 13: 233-44.
24. Ischiropoulos H, Al-Mehdi AB. Peroxynitrite-mediated oxidative protein modification. FEBS Lett 1995, 364: 279-82.
25. Gow AJ, Duran D, Malcolm S, Ischiropoulos H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett 1996, 385: 63-6.
26. Ter Steege JCA, Koster-Kamphuis L, Van Straaten EA, Forget PP, Buurman WA. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 1998, 25: 953-63.
27. Salman-Tabcheh S, Guerin MC, Tirreilles J. Nitration of tyrosyl-residues from extra- and intracellular proteins in human whole blood. Free Radic Biol Med 1995, 19: 695-8.
28. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999, 340: 115-26.
29. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98: 1487-94.
30. Holvoet P, Stassen J-M, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoprotein in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18: 100-7.
31. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20: 698-702.
32. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21: 844-8.
33. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995, 44: 1054-8.
34. Hartman ML, Crowe BJ, Biller BMK, Ho KKY, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002, 87: 477-85.
35. Gomez JM, Espadero RM, Escobar-Jimenez F, et al. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol (Oxf) 2002, 56: 329-34.
36. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999, 300: 58-62.
37. Smith JC, Lang D, McEneny J, et al. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 2002, 56: 449-55.
38. Smith JC, Evans LM, Wilkinson I, et al. Effects of GH replacement on endothelial function and large artery stiffness in GH-deficient adults: A randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) 2002, 56: 493-501.
39. Ozbey N, Aydin A, Telci A, Cakatay U. Antibodies against oxidised low density lipoprotein in hypopituitary patients with growth hormone deficiency. Endocr J 2001, 48: 579-84.
40. Pfeifer M, Verhovec R, Zizec B, Prezelj J, Poredos P, Clayton RN. Growth hormone treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999, 84: 453-7.
41. Munzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitricoxide/superoxide system. Herz 1997, 22: 58-172.
42. Böger RH, Skamira C, Bode-Böger SM, et al. Nitric oxide may mediate the haemodynamic effects of recombinant human growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996, 98: 2706-13.
43. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor 1 induced nitric oxide production by endothelial cells. Kidney Int 1994, 45: 598-604.